Skip to main content
. 2022 Jun 26;14(13):3137. doi: 10.3390/cancers14133137
BMI body mass index
C/T chemotherapy
C/T + local R/T combined chemotherapy and local radiotherapy
CA19-9 carbohydrate antigen 19-9
CC cancer cachexia
CI confidence interval
CS + adj conversion surgery with pre- or post-operative adjuvant chemotherapy
CT computed tomography
EMRs electronic medical records
Hb hemoglobin
HR hazard ratio
HU hounsfield unit
IRB Institutional Review Board
L3 the third lumbar vertebrae
mOS median overall survival
mPFS median progression-free survival
Non-CC negative cancer cachexia status
Non-SC negative sarcopenia status
OR odds ratio
OS overall survival
PC pancreatic cancer
PFS progression-free survival
SC sarcopenia
SO sarcopenic obesity
TPA total psoas area